Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

about

Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results

P2860

Q58695131-877630F6-4B66-4049-94B9-0E2AAF3423D9

P2860

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

Item

http://www.wikidata.org/entity/Q39150632

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

@en

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

@nl

type

Item

label

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

@en

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

@nl

prefLabel

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

@en

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

@nl

P1476

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus

@en

P2093

Beatriz Tejera Segura

http://www.w3.org/2001/XMLSchema#string

Christopher Wincup

http://www.w3.org/2001/XMLSchema#string

Jyoti Bakshi

http://www.w3.org/2001/XMLSchema#string

P2860

Cytokines in systemic lupus erythematosus, London, UK

Unmet medical needs in systemic lupus erythematosus

Cardiovascular disease in lupus: insights and updates

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Inflammation, atherosclerosis, and coronary artery disease

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Pathogenesis and treatment of CNS lupus.

P2888

s12016-017-8640-5

P304

352-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12016-017-8640-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anisur Rahman

P577

2018-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28853005

http://www.w3.org/2001/XMLSchema#string

P932

6244922

http://www.w3.org/2001/XMLSchema#string

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

about

P2860

P2860

Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932